Showing results (581-590 of 594) with videos related to

Sort By:
Pageof 60
European Journal of Clinical Investigation|November 1, 2020
Novel insight from the first lung transplant of a COVID-19 patientXiao-Jun Chen, Kai Li, Lei Xu, et al.
The New England Journal of Medicine|March 5, 2015
Long-term efficacy of a hepatitis E vaccineJun Zhang, Xue-Feng Zhang, Shou-Jie Huang, et al.
The Lancet Regional Health. Western Pacific|June 26, 2023
Immunogenicity and safety of heterologous immunisation with Ad5-nCOV in healthy adults aged 60 years and older primed with an inactivated SARS-CoV-2 vaccine (CoronaVac): a phase 4, randomised, observer-blind, non-inferiority trialPeng-Fei Jin, Xi-Ling Guo, Jin-Bo Gou, et al.
Nature Communications|August 15, 2025
Immunogenicity and safety of a recombinant gE-Fc fusion protein subunit vaccine for herpes zoster in adults ≥50 years of age: a randomised, active-controlled, non-inferiority trialPeng-Fei Jin, Ya-Ru Quan, Shi-Xin Xiu, et al.
National Science Review|October 22, 2021
A proof of concept for neutralizing antibody-guided vaccine design against SARS-CoV-2Li Zhang, Lei Cao, Xing-Su Gao, et al.
Lancet (London, England)|January 29, 2013
Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: a randomised, double-blind, placebo-controlled phase 2 clinical trialFeng-Cai Zhu, Zheng-Lun Liang, Xiu-Ling Li, et al.
The Pediatric Infectious Disease Journal|August 29, 2012
Reactogenicity and immunogenicity of an enterovirus 71 vaccine in Chinese healthy children and infantsFeng-Cai Zhu, Jun-Zhi Wang, Xiu-Ling Li, et al.
Nature Microbiology|April 28, 2022
An orally available Mpro inhibitor is effective against wild-type SARS-CoV-2 and variants including OmicronBao-Xue Quan, Huiping Shuai, An-Jie Xia, et al.
Lancet (London, England)|July 24, 2020
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trialFeng-Cai Zhu, Xu-Hua Guan, Yu-Hua Li, et al.
Alimentary Pharmacology & Therapeutics|March 31, 2026
Camrelizumab and Apatinib With or Without Transarterial Chemoembolisation as First-Line Treatment for Advanced Hepatocellular Carcinoma (CHANCE2311)Rong Ding, Jin-Feng Bai, Zhi-Cheng Jin, et al.
Pageof 60